Evidence map›Paper›PMID 30650527›Full record

ArticleViruses2019

Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Satyavani Kaliamurthi, Gurudeeban Selvaraj, Sathishkumar Chinnasamy, Qiankun Wang, Asma Sindhoo Nangraj, William Cs Cho, Keren Gu, Dong-Qing Wei

Abstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021
    Article
  10. The Role of Flagellin B inFrontiers in immunology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satyavani KaliamurthiCenter of Interdisciplinary Science-Computational Life Sciences, College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China. satyavani.mkk@haut.edu.cn.ORCID 0000-0002-3604-8810
Gurudeeban SelvarajCenter of Interdisciplinary Science-Computational Life Sciences, College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China. gurudeeb99@haut.edu.cn.ORCID 0000-0002-7223-3853
Sathishkumar ChinnasamyThe State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. sathishimb@sjtu.edu.cn.
Qiankun WangThe State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. wangqiankun@sjtu.edu.cn.
Asma Sindhoo NangrajThe State Key Laboratory of Microbial Metabolism, College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. sindhoo_sind@yahoo.com.
William Cs ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong. williamcscho@gmail.com.ORCID 0000-0003-4174-4586
Keren GuCenter of Interdisciplinary Science-Computational Life Sciences, College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China. gkr@haut.edu.cn.
Dong-Qing WeiCenter of Interdisciplinary Science-Computational Life Sciences, College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China. dqwei@sjtu.edu.cn.ORCID 0000-0003-4200-7502

Funding

China Postdoctoral Science Foundation 2018M632766Henan University of Technology 21450004Ministry of Science and Technology of the People's Republic of China 2016YFA0501703Natural Science Foundation of Henan Province 162300410060
6 · The paper itself

Abstract

The human papillomavirus (HPV) 58 is considered to be the second most predominant genotype in cervical cancer incidents in China. HPV type-restriction, non-targeted delivery, and the highcost of existing vaccines necessitate continuing research on the HPV vaccine. We aimed to explore the papillomaviral proteome in order to identify potential candidates for a chimeric vaccine against cervix papilloma using computational immunology and structural vaccinology approaches. Two overlapped epitope segments (23⁻36) and (29⁻42) from the N-terminal region of the HPV58 minor capsid protein L2 are selected as capable of inducing both cellular and humoral immunity. In total, 318 amino acid lengths of the vaccine construct SGD58 contain adjuvants (Flagellin and RS09), two Th epitopes, and linkers. SGD58 is a stable protein that is soluble, antigenic, and non-allergenic. Homology modeling and the structural refinement of the best models of SGD58 and TLR5 found 96.8% and 93.9% favored regions in Rampage, respectively. The docking results demonstrated a HADDOCK score of -62.5 ± 7.6, the binding energy (-30 kcal/mol) and 44 interacting amino acid residues between SGD58-TLR5 complex. The docked complex are stable in 100 ns of simulation. The coding sequences of SGD58 also show elevated gene expression in

Indexed as

Adjuvants, ImmunologicAntibodies, ViralCervix UteriComputational BiologyEpitopesFemaleGenotypeHumansOncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesProteomeVaccinologyAdjuvants, ImmunologicAntibodies, ViralEpitopesOncogene Proteins, ViralPapillomavirus VaccinesProteomecellular immunitycodon frequency distributionHPV58minor capsid proteinprophylaxisTLR agonist

Identifiers

PMID30650527
PMCPMC6357041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.